-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
-
Featured
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Featured
Using Immunotherapy to Treat Brain Tumors
In this video, William Curry, MD, discusses advancements in immunotherapy to target brain tumors. In clinical trials, he has seen the safety and strong immune activity of vaccinating patients with their own tumor cells, which has made him optimistic about the future of treatment for patients with brain tumors.
Mass General Cancer Center Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
MRI–Ultrasound Fusion–Targeted Transperineal Prostate Biopsy Complements Standard Biopsy for Detecting Perineural Invasion
-
Joseph H. Schwab, MD, MS
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopaedic Surgery, Harvard Medical School
Recent Article
Adding High-Dose Radiation to Surgery Confers Survival Benefit in Patients With Chordoma
-
Kerry L. Reynolds, MD
Clinical Director, Inpatient Oncology Units, Director, Severe Immunotherapy Complications Program
Recent Article
Researchers Chart the Course of Severe Checkpoint Inhibitor-related Colitis -
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Bamlanivimab–Etesevimab for Mild to Moderate COVID-19 in Patients at High Risk of Progression
-
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Immune Cell Hubs Interact with Malignant Cells in Human Colorectal Cancer
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Review: Implications of IDH Mutations for Success of Glioma Immunotherapy
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
